FDA officials and representatives from both the generic and branded drug industries spent two days hashing out next steps for development of abuse-deterrent opioids. According to MedPage Today, the two topics on the table were reviewing draft guidance for the development of generic versions of abuse-deterrent opioids and developing a standard in vitro testing methods to characterize a drug’s abuse-deterrent properties. The meeting is in line with the FDA’s strategic plan for mitigating the opioid epidemic.
Read complete coverage here.